Patents Assigned to Memorial Sloan-Kettering Cancer Center
  • Publication number: 20200332253
    Abstract: The presently disclosed subject matter provides for in vitro methods of inducing differentiation of stem cells (e.g., human stem cells) into somatotrophs, and differentiated cells generated by such methods. The presently disclosed subject matter also provides for uses of such cells for treating growth hormone deficiency.
    Type: Application
    Filed: May 7, 2020
    Publication date: October 22, 2020
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Viviane Tabar, Jinghua Piao
  • Publication number: 20200330574
    Abstract: The present disclosure provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to an immunoresponsive cell comprising an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR)), and expressing increased level of IL-36. In certain embodiments, the engineered immunoresponsive cells are antigen-directed and have enhanced immune-activating properties.
    Type: Application
    Filed: May 13, 2020
    Publication date: October 22, 2020
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Anthony Daniyan, Renier J. Brentjens
  • Patent number: 10810736
    Abstract: The present disclosure is directed to systems and methods for classifying biomedical images. A feature classifier may generate a plurality of tiles from a biomedical image. Each tile may correspond to a portion of the biomedical image. The feature classifier may select a subset of tiles from the plurality of tiles by applying an inference model. The subset of tiles may have highest scores. Each score may indicate a likelihood that the corresponding tile includes a feature indicative of the presence of the condition. The feature classifier may determine a classification result for the biomedical image by applying an aggregation model. The classification result may indicate whether the biomedical includes the presence or lack of the condition.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: October 20, 2020
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Thomas Fuchs, Gabriele Campanella
  • Patent number: 10811138
    Abstract: Described herein are systems and methods of selecting treatment parameters values for treating skin lesions. A device may establish a treatment parameter selection model using a training dataset. The training dataset may include a plurality of examples. Each example may include a sample image of an example skin lesion to which a treatment is administered using an applicator. Each example may include a first label indicating success or failure of the treatment. Each example may include a second label corresponding to treatment parameters defining the treatment. The device may identify an input image. The device may determine that the input image corresponds to a skin lesion based on visual characteristics of the input image. The device may apply the treatment parameter selection model to the input image to output a recommended treatment to apply. The device may store an association between the input image and the recommended treatment.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: October 20, 2020
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Allan C. Halpern, Steven Q. Wang, Douglas Comrie Canfield
  • Patent number: 10806808
    Abstract: The present disclosure describes a non-linear compartmental model using PET-derived data to predict, on a patient-specific basis, the optimal therapeutic dose of cargo carrying antibody (e.g., huA33) such as radiolabeled antibody, the antigen occupancy, residency times in normal and malignant tissues, and the cancer-to-normal tissue (e.g., colorectal cancer-to-normal colon tissue) therapeutic index. In addition, the non-linear compartmental model can be readily applied to the development of strategies such as multi-step targeting (MST) designed to further improve the therapeutic indices of RIT.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: October 20, 2020
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Pat B. Zanzonico, Sarah M. Cheal, Steven M. Larson, Joseph Reginald Osborne, Edward Komin Fung, David Ulmert
  • Publication number: 20200325223
    Abstract: The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., multiple myeloma). It relates to anti-CD56 antibodies, chimeric antigen receptors (CARs) that specifically target human CD56, and immunoresponsive cells comprising such CARs. The presently disclosed CD56-specific CARs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Application
    Filed: June 25, 2020
    Publication date: October 15, 2020
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE
    Inventors: Michel Sadelain, Reuben Benjamin, Dimiter S. Dimitrov, Yang Feng
  • Patent number: 10800849
    Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: October 13, 2020
    Assignees: Agenus Inc., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.
    Inventors: Ana M. Gonzalez, Nicholas S. Wilson, Dennis J. Underwood, Volker Seibert, Olivier L├ęger, Marc Van Dijk, Roberta Zappasodi, Taha Merghoub, Jedd David Wolchok, David Schaer, Gerd Ritter, Takemasa Tsuji
  • Publication number: 20200316198
    Abstract: The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of a recombinant modified vaccinia Ankara (MVA) virus comprising an MVA harboring a human Fms-like tyrosine kinase 3 ligand (hFlt3L) (MVA-hFtl3L). The foregoing vaccinia Ankara (MVA) virus can be delivered to tumor cells of a subject afflicted with a malignant solid tumor, to treat the tumor. In a related aspect, the present disclosure concerns a recombinant modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MV At.E3L) modified to express human Fins-like 5 tyrosine kinase 3 ligand (hFlt3L) isolated, suitable for use as an immunotherapeutic agent against a malignant solid tumor.
    Type: Application
    Filed: April 10, 2020
    Publication date: October 8, 2020
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Liang DENG, Stewart SHUMAN, Jedd WOLCHOK, Taha MERGHOUB, Weiyi WANG, Peihong DAI, Ning Yang
  • Publication number: 20200315981
    Abstract: Methods and compositions described herein use polysaccharide nanoparticles (or polysaccharide-coated nano -particles) to retain and deliver unaltered therapeutic agents to sites of disease. The polysaccharide nanoparticles are non-covalently associated with the unaltered therapeutic agent. The polysaccharide is able to retain cargo (drugs, diagnostics, etc.) without chemical modification of the agent. The nanoparticle maintains its association with the agent through non-covalent interactions but releases its agent in response to changes in the microenvironment, e.g., at the site of cancer cells or cancer tissue.
    Type: Application
    Filed: October 21, 2019
    Publication date: October 8, 2020
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Jan GRIMM, Charalambos KAITTANIS, Travis M. SHAFFER
  • Publication number: 20200317781
    Abstract: The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen recognizing receptor and one of a chimeric costimulatory receptor. Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
    Type: Application
    Filed: April 13, 2020
    Publication date: October 8, 2020
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Christopher C. Kloss, Michel Sadelain
  • Publication number: 20200317777
    Abstract: The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of chimeric antigen receptors (CARs) and engineered immunoresponsive cells comprising the same. The engineered immunoresponsive cells comprising the novel CARs are antigen-directed and have extended persistence without compromising function.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 8, 2020
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Judith Feucht, Mohamad Hamieh, Jie Sun, Jorge A. Mansilla-Soto
  • Patent number: 10792284
    Abstract: The use of mitogen activated kinase inhibition therapy in combination with receptor tyrosine kinase therapy for the treatment of cancer is described.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: October 6, 2020
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Scott W. Lowe, Neal Rosen, Eusebio Manchado-Robles, Susann Weissmueller
  • Patent number: 10793570
    Abstract: The present invention provides methods for radiolabeling compounds useful as Hsp90 inhibitors. The present invention also provides intermediates useful in such methods, and compositions of radiolabeled compounds. The present invention provides, among other things novel methods for the synthesis of radiolabeled compounds. In certain embodiments, the present invention provides compounds of formula I.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: October 6, 2020
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Stefan O. Ochiana, NagaVaraKishore Pillarsetty, Tony Taldone, Gabriela Chiosis
  • Publication number: 20200291112
    Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to and neutralize the activity of A33 protein. The antibodies of the present technology are useful in methods for detecting and treating an A33-positive cancer in a subject in need thereof.
    Type: Application
    Filed: September 21, 2018
    Publication date: September 17, 2020
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Zhihao WU, Hong XU, Nai-Kong CHEUNG
  • Publication number: 20200291433
    Abstract: The presently disclosed subject matter provides for expression cassettes that allow for expression of a globin gene or a functional portion thereof, vectors comprising thereof, and cells transduced with such expression cassettes and vectors. The presently disclosed subject matter further provides methods for treating a hemoglobinopathy in a subject comprising administering an effective amount of such transduced cells to the subject.
    Type: Application
    Filed: June 2, 2020
    Publication date: September 17, 2020
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Annalisa Cabriolu
  • Publication number: 20200292640
    Abstract: Described herein are micro-coil hyperpolarized NMR systems and methods for measuring metabolic flux in living and non-living samples. Such systems can perform high throughput measurements (with multiple coils) of metabolic flux without destroying the material, making it useful to analyze tumor biopsies, cancer stem cells, and the like. In certain embodiments, a hyperpolarized micromagnetic resonance spectrometer (HMRS), described herein, is used to achieve real-time, significantly more sensitive (e.g., 103-fold more sensitive) metabolic analyses of live cells or non-living samples. In this platform, a suspension mixed with hyperpolarized metabolites is loaded into a miniaturized detection coil (e.g., about 2 ?L), where the flux analysis can be completed within a minute without significant changes in viability. The sensitive and rapid analytical capability of the provided systems enables rapid assessment of metabolic changes by a given drug, which may direct therapeutic choices in patients.
    Type: Application
    Filed: March 8, 2017
    Publication date: September 17, 2020
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Kayvan RAHIMI-KESHARI, Sangmoo JEONG
  • Patent number: 10772862
    Abstract: Methods and compositions for treating Ras-related cancers are provided that involve targeting lipid scavenging. Methods and compositions for identifying and/or characterizing more or less responsive cancers are also provided.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: September 15, 2020
    Assignees: The Trustees of Princeton University, Memorial Sloan Kettering Cancer Center
    Inventors: Joshua Rabinowitz, Jurre Kamphorst, Craig Thompson, Justin Cross
  • Publication number: 20200285890
    Abstract: Presented herein are systems and methods of clustering images using encoder-decoder models. A computing system may identify tiles derived from an image. Each tile may have a first dimension. The computing system may apply an image reconstruction model to the tiles. The image reconstruction model may include an encoder block having a first set of weights to generate embedding representations corresponding to the tiles. Each embedding representation may have a second dimension lower than the first dimension. The image reconstruction model may include a decoder block having a second set of weights to generate reconstructed tiles corresponding to the embedding representations. The computing system may apply a clustering model comprising a feature space to the embedding representations to classify each tile to one of a plurality of conditions.
    Type: Application
    Filed: March 5, 2020
    Publication date: September 10, 2020
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Thomas J. Fuchs, Hassan Muhammad
  • Publication number: 20200282054
    Abstract: Disclosed is a method for increasing susceptibility of cancer cells to ionizing radiation by delivering to the cells a radiosensitizing agent that has one of the following properties: it perturbs the process of chromosome segregation thereby increasing chromosome missegregation; or (b) it is an inhibitor of an agent that promotes faithful chromosome segregation induces numeric chromosome instability in said cells and this instability is induced substantially simultaneously with or closely prior to or closely after irradiating the cells. Examples of such radiosensitizing agent include inhibitors of one or more of the following: Kif2b, MCAK, MPS1, Eg5/Kinesin-5 5, Polo-like kinase 4, MCAK, Bub1 and Hec1. Such agents specifically target proteins involved in maintaining or promoting faithful chromosome segregation.
    Type: Application
    Filed: March 13, 2020
    Publication date: September 10, 2020
    Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Samuel F. BAKHOUM, Zaki I. BASSEM, Duane A. COMPTON
  • Patent number: 10765711
    Abstract: The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of poxviruses, specifically the replication competent attenuated vaccinia virus with deletion of thymidine kinase (VC-TK?) with and without the expression of human Flt3L or GM-CSF as oncolytic and immunotherapy. The foregoing poxviruses can also be used in combination with immune checkpoint blocking agents. The foregoing poxviruses can also be inactivated via Heat or UV-treatment and the inactivated virus can be used as immunotherapy either alone or in combination with immune checkpoint blocking agents.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: September 8, 2020
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Liang Deng, Stewart Shuman, Jedd Wolchok, Taha Merghoub, Weiyi Wang, Peihong Dai, Ning Yang